Brought to you by 
Sanofi gets rights to Exelixis' XL147 and XL765
11 Dec 2015
Executive Summary
Three weeks after teaming up with Boehringer Ingelheim for immunology therapeutics, potentially gaining up to $354mm in that deal, Exelixis is now licensing two of its cancer candidates--XL147 and XL675--to Sanofi-Aventis in a collaboration that could bring the biotech over $1bn.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sanofi gets rights to Exelixis' XL147 and XL765
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice